Loading…
Employees: 2,662
Size Xiangxue Pharmaceutical (300147.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $502M, the 3862nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.08 on 6 Nov 2026.
Performance Over six months the shares fell 49.3%, against -18.1% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 2.9% over the last twelve months (peer median +9.8%); the operating margin is -38.5% (peer median 10.0%).
Valuation It trades at 3.3× enterprise value to sales against a peer median of 4.0× (6th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is -12%, so the hurdle is +59 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 38.5 points below its cost of capital (6.8% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.51B | CN¥1.59B | CN¥1.85B | CN¥2.29B | CN¥2.18B |
| Revenue growth | — | -14% | -19% | +5% | — |
| Gross profit | CN¥499M | CN¥327M | CN¥339M | CN¥685M | CN¥448M |
| EBITDA | n/a | CN¥75.2M | -CN¥873,910 | CN¥262M | CN¥51.1M |
| Net income | -CN¥1.45B | -CN¥1.39B | -CN¥859M | -CN¥389M | -CN¥530M |
| Free cash flow | CN¥25.8M | CN¥118M | -CN¥16.8M | CN¥208M | -CN¥139M |
| Capital expenditure | CN¥27.1M | CN¥21.5M | CN¥35.2M | CN¥56.0M | CN¥367M |
| Total debt | CN¥1.39B | CN¥4.02B | CN¥3.77B | CN¥3.79B | CN¥3.67B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300147.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.0% | -8.5% | 10th highest of 21 |
| 6-month return | -49.3% | -18.1% | 2nd lowest of 20 |
| Distance from 52-week high | -54.8% | -41.9% | 3rd lowest of 21 |
| Revenue growth (TTM) | +2.9% | +9.8% | 8th lowest of 19 |
| Operating margin | -38.5% | 10.0% | 4th lowest of 18 |
| EV / Sales | 3.3× | 4.0× | 6th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 47.1% | 6.7% | most demanding of 8 |
| Growth delivered (Del g) | -12.3% | +6.3% | lowest of 8 |
| Hurdle (Req g minus delivered) | +59.4 pp | +1.1 pp | most demanding of 8 |
| ROIC minus cost of capital | -38.5 pp | -2.1 pp | 5th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |